BioNTech urges CureVac shareholders to tender by early December deadline

BioNTech is pressing CureVac shareholders to submit their shares by 6:00 p.m. Eastern Time on Tuesday December 2, 2025 to guarantee processing before the scheduled expiration of BioNTech’s exchange offer at 9:00 a.m. Eastern Time on December 3. Company filings and corporate notices published December 1 and December 2 explain that operational deadlines at the Depository Trust Company and the exchange agent create an effective tender cutoff earlier than the technical expiry.

CureVac shareholders overwhelmingly approved matters related to the exchange at an extraordinary general meeting on November 25, clearing a key corporate hurdle for the transaction. Under the exchange terms set out in filing materials and press statements, CureVac holders would receive a fixed ratio of BioNTech American Depositary Shares per CureVac share. The exchange ratio and mechanics were determined according to a pre agreed volume weighted average price calculation, and the offer is conditioned on reaching a minimum acceptance threshold reported at 80 percent of outstanding shares. That threshold could be adjusted if BioNTech elects to extend the offer.

The two day processing window reflects the practicalities of cross border securities settlement and ADS issuance rather than a change in economic terms. Depository Trust Company cutoffs and the exchange agent’s need to confirm certificates and transfers mean that tenders received after the 6:00 p.m. processing deadline may not be reflected by the formal expiration. BioNTech’s advisories emphasize that shareholders who want to participate in the exchange must factor in those operational timelines.

Market participants will watch acceptance levels closely. If the 80 percent threshold is met, BioNTech would secure broad control through an equity exchange rather than a cash purchase, limiting immediate cash outflow while increasing its ADS float. If acceptance falls short, the company may extend the offer or amend conditions, a step that could introduce further uncertainty and market volatility. Shareholders who convert to BioNTech ADS will also face changes in liquidity and market access, since ADS trade on U.S. exchanges and are subject to U.S. settlement conventions.

Strategically, the exchange represents consolidation in the mRNA sector that accelerated after the pandemic, as firms seek scale to fund research and commercial expansion in a more constrained capital environment. For investors and policymakers, the deal underscores how corporate actions interact with settlement mechanics and shareholder decision timing. Regulators will monitor any completion for competition and national security considerations given the strategic nature of vaccine technologies.

With the clock running on December 2, shareholders who intend to participate must act to meet the processing deadline. Company filings and notices published December 1 and December 2 provide the formal mechanics and conditions for the offer, and indicate that the decisive period for shareholders and markets is now.